Abstract 272P
Background
5-fluorouracil (5-FU) is a major component of chemotherapy regimens in gastrointestinal (GI) cancers. Mutation in Dihydropyrimidine Dehydrogenase (DPD) gene can cause severe 5-FU related toxicity. Identifying the mutation helps in predicting the toxicity and adjusting dose of 5-FU. Our study assesses and analyze the utility of DPD testing at our center.
Methods
Data of GI cancer patients who has been tested for DPD enzyme while planning chemotherapy (for both adjuvant and palliative settings) was extracted from our center’s electronic records from the 1st June 2016 to 31st December 2021 and evaluated. We collected demographics of the patients, genotypes of DPD gene, disease status, chemotherapy type and the associated toxicities.
Results
Total 211 patients were tested for the DPD gene with median age of 66 years (Female=78). 120 patients were found to have mutation. There were 6 different DPD genotypes in our dataset. Among mutated ones, 36% were female. Seven patients were homozygous for some DPD gene variants, most common was *9A (c.85 T>C; p.C29R) genotype. While 2 out of 7 had severe diarrhea (Grade 3/4, CTCAE V.5) during chemotherapy, no patient died of toxicity. Among mutated vs non-mutated patients, grade 3/4 diarrhoea was 25% vs 38% (Chi Sq (1, N = 65) = 4.39, p = .035), anemia was 10% vs 9% (Chi Sq (1, N=21) = 0.0007, p= .978), neutropenia was 9% vs 4% (Chi Sq (1, N=15) =1.78, p= .181), thrombocytopenia was 5% vs 3% (Chi Sq (1, N=9) = 0.36, p= .544), mucositis was 6% vs 1% (Chi Sq (1, N=9) = 3.92, p= .047). Most patients with Grade 3/4 toxicity were on combination chemotherapy. We found 9 different DPD genotypes in our population. Among them, *9A (c.85 T>C; p.C29R) caused most severe GI toxicity, *2A (c.14+1 G>A) genotype resulted in severe hematological and GI toxicity. We lost one patient to toxicity having heterozygous *6 (2194 G/A; p.V732I) mutation.
Conclusions
DPD gene testing can help in predicting the toxicity to 5-FU based chemotherapy. We found that diarrhea and mucositis were related to the DPD gene mutation more than anemia, neutropenia and thrombocytopenia. Genotype analysis should be an important part of the treatment plan for GI cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tanuj Chawla.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
265P - Tumor-agonistic genomic profiling
Presenter: Naomi Hayashi
Session: Poster viewing 03
266P - Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Presenter: Xuchao Zhang
Session: Poster viewing 03
267P - Genomic landscape of non-small cell lung cancer (NSCLC) in India using circulating tumor DNA (ctDNA) in clinical practice
Presenter: Amit Rauthan
Session: Poster viewing 03
269P - MET alterations in EGFR mutated NSCLC: A lesser known evil
Presenter: Mansi Sharma
Session: Poster viewing 03
271P - Prospective study on toxicity profile of immunotherapy in a Indian population: A real-world experience
Presenter: Kaushik R
Session: Poster viewing 03